2024
Durlobactam in combination with β-lactams to combat Mycobacterium abscessus
Shin E, Dousa K, Taracila M, Bethel C, Nantongo M, Nguyen D, Akusobi C, Kurz S, Plummer M, Daley C, Holland S, Rubin E, Bulitta J, Boom W, Kreiswirth B, Bonomo R. Durlobactam in combination with β-lactams to combat Mycobacterium abscessus. Antimicrobial Agents And Chemotherapy 2024, 69: e01174-24. PMID: 39714147, PMCID: PMC11823594, DOI: 10.1128/aac.01174-24.Peer-Reviewed Original Research
2021
1390. Durlobactam, a Diazabicyclooctane (DBO) β-lactamase Inhibitor (BLI), Inhibits BlaC and Peptidoglycan (PG) Transpeptidases of Mycobacterium tuberculosis (Mtb): A Novel Approach to Therapeutics for Tuberculosis (TB)?
Nguyen D, Bethel C, Taracilla M, Li Q, Dousa K, Kurz S, Nguyen L, Kreiswirth B, Boom W, Bonomo R. 1390. Durlobactam, a Diazabicyclooctane (DBO) β-lactamase Inhibitor (BLI), Inhibits BlaC and Peptidoglycan (PG) Transpeptidases of Mycobacterium tuberculosis (Mtb): A Novel Approach to Therapeutics for Tuberculosis (TB)? Open Forum Infectious Diseases 2021, 8: 780-780. PMCID: PMC8643912, DOI: 10.1093/ofid/ofab466.1582.Peer-Reviewed Original ResearchB-lactamMultidrug-resistant TBTreatment of TBNovel therapiesMtb H37RvAvibactamRelebactamCarbapenemsClavulanateMicrodilution methodAcyl-enzyme complexTherapeutic potentialDurlobactamMeropenemMICDual actionTranspeptidasePre-incubationDiazabicyclooctaneMtbAmoxicillinPeriod of pre-incubationTuberculosis
2019
Molecular epidemiology of Campylobacter isolates from broiler slaughterhouses in Tripoli, North of Lebanon
Rafei R, Al Kassaa I, Osman M, Dabboussi F, Hamze M. Molecular epidemiology of Campylobacter isolates from broiler slaughterhouses in Tripoli, North of Lebanon. British Poultry Science 2019, 60: 675-682. PMID: 31321996, DOI: 10.1080/00071668.2019.1645945.Peer-Reviewed Original ResearchMeSH KeywordsAbattoirsAnimalsAnti-Bacterial AgentsCampylobacterCampylobacter InfectionsCecumChickensDrug Resistance, BacterialElectrophoresis, Gel, Pulsed-FieldFlagellinFoodborne DiseasesGenetic VariationHumansLebanonPolymerase Chain ReactionPolymorphism, Restriction Fragment LengthPoultry DiseasesPrevalenceSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationConceptsAntibiotic resistance profilesErtapenem resistanceMolecular epidemiologyReal burdenResistance profilesAntibiotic resistanceRestriction fragment length polymorphismNorth of LebanonFragment length polymorphismEpidemiologyField gel electrophoresisCampylobacterLength polymorphismBroiler slaughterhousesBroilersIsolatesSlaughterhouseGentamicinAmoxicillinErythromycin
2018
β‑Lactam Biotransformations Activate Innate Immunity
Oh J, Patel J, Park HB, Crawford JM. β‑Lactam Biotransformations Activate Innate Immunity. The Journal Of Organic Chemistry 2018, 83: 7173-7179. PMID: 29616809, DOI: 10.1021/acs.joc.8b00241.Peer-Reviewed Original ResearchConceptsHuman microbiota compositionImmune responseImmune functionMicrobiota compositionInnate immunityBroad immunomodulatory mechanismPatient's immune responseClinical trial studyCommon resistance determinantsMicrobiome-dependent mannerImmunomodulatory mechanismsNF-κBTrial studyBacterial infectionsImmunomodulatory interactionsMinimal long-term impactAntibioticsΒ-lactamaseAmoxicillinHuman leukemic monocytesLeukemic monocytesResistance determinantsBiotransformation productsImmunityMolecular mechanisms
2017
Secondary antibiotic resistance of Helicobacter pylori isolates in Israeli children and adults
Khoury J, Geffen Y, Shaul R, Sholy H, Chowers Y, Saadi T. Secondary antibiotic resistance of Helicobacter pylori isolates in Israeli children and adults. Journal Of Global Antimicrobial Resistance 2017, 10: 182-185. PMID: 28732784, DOI: 10.1016/j.jgar.2017.05.017.Peer-Reviewed Original ResearchConceptsH. pylori culturePositive H. pylori culturePylori cultureTherapeutic regimensH. pyloriRambam Health Care CampusSecondary antibiotic resistanceHelicobacter pylori infectionHealth Care CampusAntibiotic resistanceH. pylori strainsHelicobacter pylori isolatesStandard therapyPylori infectionGastric biopsiesSecondary antimicrobial resistanceLEV resistancePylori isolatesPatientsAntimicrobial susceptibilityClarithromycinPylori strainsMetronidazoleAmoxicillinAntimicrobial resistance
2014
Comparison of oral amoxicillin given thrice or twice daily to children between 2 and 59 months old with non-severe pneumonia: a randomized controlled trial
Vilas-Boas A, Fontoura M, Xavier-Souza G, Araújo-Neto C, Andrade S, Brim R, Noblat L, Barral A, Cardoso M, Nascimento-Carvalho C, Matutino A, Barreto B, Silva C, Braga D, Oliveira F, Nogueira G, Oliveira Í, Lorgetto I, Costa I, Araripe J, Vieira J, Neiva L, Santana M, Nobre-Bastos M, Santos P, Câmara S, Carneiro S, Sirmos U, Araújo V, Silva C, Vilas-Boas C, Gantois D, Azevedo F, Maia J, Pirajá L, Jesus P, Fonseca T, Vilar T. Comparison of oral amoxicillin given thrice or twice daily to children between 2 and 59 months old with non-severe pneumonia: a randomized controlled trial. Journal Of Antimicrobial Chemotherapy 2014, 69: 1954-1959. PMID: 24648506, DOI: 10.1093/jac/dku070.Peer-Reviewed Original ResearchConceptsNon-severe pneumoniaTreatment failureOral amoxicillinFirst-line therapyChildhood pneumoniaPrimary outcomeTreat analysisRespiratory complaintsBlinded investigationDaily dosesChest radiographsPatient allocationPneumoniaPatientsIndependent radiologistsAmoxicillinProtocol analysisThriceMonthsChildrenParticipantsFailureConcordant readingsPlaceboTherapy
2010
Clinical failure among children with nonsevere community-acquired pneumonia treated with amoxicillin
Fontoura M, Araújo-Neto C, Andrade S, Brim R, Matutino A, Silva C, Santana M, Nobre-Bastos M, Oliveira F, Barreto B, Santos P, Noblat L, Cardoso M, Nascimento-Carvalho C, Group T. Clinical failure among children with nonsevere community-acquired pneumonia treated with amoxicillin. Expert Opinion On Pharmacotherapy 2010, 11: 1451-1458. PMID: 20408745, DOI: 10.1517/14656561003777034.Peer-Reviewed Original ResearchConceptsClinical failureDays of treatmentRisk factorsNonsevere community-acquired pneumoniaAdverse effect frequencyPersistence of feverRadiographic pulmonary infiltratesCommunity-acquired pneumoniaIndependent risk factorClinical failure rateNonsevere pneumoniaPulmonary infiltratesAdverse eventsPleural effusionRespiratory complaintsClinical findingsDifficulty breathingAdverse reactionsSevere diseasePneumonia diagnosisCystic fibrosisMultivariate analysisDemographic dataAmoxicillinOlder children
2008
Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug‐induced liver injury
Rochon J, Protiva P, Seeff LB, Fontana RJ, Liangpunsakul S, Watkins PB, Davern T, McHutchison JG, Network D. Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug‐induced liver injury. Hepatology 2008, 48: 1175-1183. PMID: 18798340, PMCID: PMC3618289, DOI: 10.1002/hep.22442.Peer-Reviewed Original ResearchConceptsRoussel Uclaf Causality Assessment MethodDrug-induced liver injuryCausality Assessment MethodLiver injuryDrug-induced liver injury casesDrug-Induced Liver Injury NetworkLiver injury casesCases of hepatotoxicityInterrater reliabilityStrength of associationDeviation ageCase of drugsTest-retest reliabilityTest-retest differencesCausality assessmentInjury casesInjuryFive-category scaleSame reviewersSame assessorPhenytoinReviewersIsoniazidAmoxicillinResearch settings
2001
Morth American randomized trial of single-triple capsule (bismuth subcitrate, metronidazele, tetracycline) plus omeprazole vs. Omeprazole, amoxicillin, and clarithremycin for H. pylori eradication
Laine L, Hunt R, El-Zimaity H, Osato M, Spenard J, Pharma A. Morth American randomized trial of single-triple capsule (bismuth subcitrate, metronidazele, tetracycline) plus omeprazole vs. Omeprazole, amoxicillin, and clarithremycin for H. pylori eradication. Gastroenterology 2001, 120: a580. DOI: 10.1016/s0016-5085(08)82885-5.Peer-Reviewed Original Research
2000
H. pylori antibiotic resistance, eradication, and emergent resistance in U.S. double-blind trials of esomeprazole, clarithromycin, and amoxicillin
Laine L, Fennerty M, Suchower L, Probst P, Osato M, Levine J. H. pylori antibiotic resistance, eradication, and emergent resistance in U.S. double-blind trials of esomeprazole, clarithromycin, and amoxicillin. Gastroenterology 2000, 118: a498. DOI: 10.1016/s0016-5085(00)84113-x.Peer-Reviewed Original Research
1998
Twice-daily 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for H. Pylori eradication in duodenal ulcer disease: Results of 3 multicenter, double-blind, U.S. Trials
Laine L, Suchower L, Connors A, Frantz J, Neil G. Twice-daily 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for H. Pylori eradication in duodenal ulcer disease: Results of 3 multicenter, double-blind, U.S. Trials. Gastroenterology 1998, 114: a193. DOI: 10.1016/s0016-5085(98)80787-7.Peer-Reviewed Original ResearchAccuracy of CLOtest after Helicobacter pylori therapy
Laine L, Suchower L, Johnson E, Ronca P, Neil G. Accuracy of CLOtest after Helicobacter pylori therapy. Gastrointestinal Endoscopy 1998, 47: 250-253. PMID: 9540877, DOI: 10.1016/s0016-5107(98)70321-9.Peer-Reviewed Original ResearchConceptsHelicobacter pylori therapyPylori therapyOmeprazole/amoxicillinCompletion of therapyDouble-blind trialRapid urease testingMore effective therapiesEndoscopic biopsy testsOmeprazole therapyAdditional therapyMost patientsDual therapyUnsuccessful treatmentUrease testingEffective therapyPositive testPatientsH. pyloriTherapyCLOtestBiopsy testsDecreased numberWeeksNegative resultsAmoxicillin
1992
A Controlled Trial of Antimicrobial Prophylaxis for Lyme Disease after Deer-Tick Bites
Shapiro E, Gerber M, Holabird N, Berg A, Feder H, Bell G, Rys P, Persing D. A Controlled Trial of Antimicrobial Prophylaxis for Lyme Disease after Deer-Tick Bites. New England Journal Of Medicine 1992, 327: 1769-1773. PMID: 1435930, DOI: 10.1056/nejm199212173272501.Peer-Reviewed Original ResearchConceptsDeer tick biteRisk of infectionProphylactic antimicrobial treatmentLyme diseaseB. burgdorferiAntimicrobial treatmentDeer ticksPlacebo-controlled trialPlacebo-treated subjectsCare of personsAsymptomatic seroconversionAntimicrobial prophylaxisErythema migransClinical manifestationsPolymerase chain reactionLate manifestationPlaceboDiseaseSerum samplesInfectionBorrelia burgdorferiBiteChain reactionAmoxicillinBurgdorferi
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply